RDD Pharma has secured $9.5m in a series B round that included Pharmascience, and will use the capital to fund clinical trials.
Generic drug manufacturer Pharmascience has invested in Israel-based gastrointestinal pharmaceutical developer RDD Pharma as part of a $9.5m series B round.
RDD raised $6m of the funding from Pharmascience and an undisclosed life science fund, and the rest from investment firms OrbiMed and Capital Point. The company had previously received $7.2m in funding from OrbiMed in 2012.
Founded in 2009, RDD Pharma is developing a treatment for chronic anal fissures and another for faecal incontinence in patients with spinal cord…